wam.ae
Cure8 news brief
Limited source text
What Cure8 can confirm
What We Know
Cure8 does not have enough reliable source text to summarize this article yet. Based on the article title and source metadata, this appears to be a regulatory update related to Crohn's disease, Guselkumab, IL-23 inhibitor, and Medications. Use the original source link for the full details.
What Is Not Available
The source did not provide enough reliable article text for a source-grounded Cure8 brief. Study details, results, and limitations should be checked in the original source.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationwam.ae
Indexed viaBing News
Source typeMainstream News
PublishedApr 16, 2025, 5:52 AM
Cure8 could not retrieve enough reliable source text to summarize this article. This page is based on the article title, source metadata, and Cure8 topic classification.
FDA Approves Tremfya for Active Crohn Disease in Adults
Cure8 found this source from wyomingnews.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Guselkumab. Open the original article for the full details.
FDA Approves Both SC and IV Guselkumab for Crohn's Disease Among Adult Patients
Cure8 found this source from hmpgloballearningnetwork.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Guselkumab, and IL-23 inhibitor. Open the original article for the full details.
FDA Expands Guselkumab Approval to Crohn's Disease
Cure8 found this source from medpagetoday.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Guselkumab. Open the original article for the full details.